INKON Life Technology Co Ltd
SZSE:300143
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
6.75
10.99
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
INKON Life Technology Co Ltd
INKON Life Technology Co Ltd
Cash & Cash Equivalents
INKON Life Technology Co Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
INKON Life Technology Co Ltd
SZSE:300143
|
Cash & Cash Equivalents
¥413.4m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
40%
|
CAGR 10-Years
31%
|
|
|
H
|
Hygeia Healthcare Holdings Co Ltd
HKEX:6078
|
Cash & Cash Equivalents
¥853.8m
|
CAGR 3-Years
30%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
|
A
|
Aier Eye Hospital Group Co Ltd
SZSE:300015
|
Cash & Cash Equivalents
¥5.5B
|
CAGR 3-Years
5%
|
CAGR 5-Years
26%
|
CAGR 10-Years
24%
|
|
|
X
|
XiAn International Medical Investment Co Ltd
SZSE:000516
|
Cash & Cash Equivalents
¥667.3m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-3%
|
|
|
H
|
Huaxia Eye Hospital Group Co Ltd
SZSE:301267
|
Cash & Cash Equivalents
¥3.9B
|
CAGR 3-Years
98%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Sanbo Hospital Management Group Ltd
SZSE:301293
|
Cash & Cash Equivalents
¥822.1m
|
CAGR 3-Years
16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
INKON Life Technology Co Ltd
Glance View
INKON Life Technology Co., Ltd. engages in the research, development, production and sale of edible fungus. The company is headquartered in Qingdao, Shandong and currently employs 1,791 full-time employees. The company went IPO on 2011-04-22. Its medical services focus on cancer prevention, diagnosis, treatment and rehabilitation. The firm is also engaged in the research and development, manufacture and sales of medical equipment, as well as medical software development. Its medical equipment mainly include MASEP digital radiotherapy equipment, MASEP Gamma Knife and other large medical equipment. The firm distributes its products within domestic market and to overseas markets.
See Also
What is INKON Life Technology Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
413.4m
CNY
Based on the financial report for Sep 30, 2024, INKON Life Technology Co Ltd's Cash & Cash Equivalents amounts to 413.4m CNY.
What is INKON Life Technology Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
31%
Over the last year, the Cash & Cash Equivalents growth was -44%. The average annual Cash & Cash Equivalents growth rates for INKON Life Technology Co Ltd have been -19% over the past three years , 40% over the past five years , and 31% over the past ten years .
You don't have any saved screeners yet
